Molecular genetic analysis of the interleukin 6 and tumor necrosis factor α gene polymorphisms in multiple myeloma

Molekulyarnaya Biologiya

Volumn 37, Issue 3, 2003, Pages 420-424

  Yakupova, E V ^a   Grinchuk, O V ^a   Kalimullina, D Kh ^b   Bakirov, B A ^b   Galimova, R R ^b   Makarova, O V ^a   Khusnutdinova, E K ^a   Viktorova, T V ^a  

^a INSTITUTE OF BIOCHEMISTRY AND GENETICS   (Russian Federation)

^b Ufa Institute of Occupational Health and Human Ecology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; MOLECULAR GENETICS; MULTIPLE MYELOMA; ADULT; AGED; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; PROMOTER REGION; RUSSIAN FEDERATION;

ADULT; AGED; BASHKIRIA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141834154     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lichtenstain A., Tu Y., Fadu C., Vesior R., Berenson J. 1995. Interleukin-6 ingibits apoptosis of malignant plasma cells. Cell Immunol. 162, 248-255.
2. Hallek M., Bergsagel P.L., Anderson K.C. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 91, 3-21.
3. Fayad L., Keating M.J., Reuben J.M. et al. 2001. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 97, 256-263.
4. Hardin J., MacLeod S., Grigorieva I. et al. 1994. Interleukin-6 prevents dexametasone-induced myeloma cell death . Blood. 84, 3063-3070.
5. Nachbaur D.M., Herold M., Maneschg A., Huber A. 1991. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Annu. Hematol. 62, 54-58.
6. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M.C., Rieux C., Coiffier B. 1996. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br. J. Hematology. 93, 352-359.
7. Mathew C.C. 1984. The isolation of high molecular weight eucariotic DNA. Meth. Mol. Biol. L.: Human Press, 2, 31-34.
8. Fernández-Real J.M., Broch M., Vendrell J. et al. 2000. Interleukin-6 gene polymorphism and lipid anomalities in healthy subjects. J. Clin. Endocrinol. Metab. 85, 1334-1339.
9. Fishman D., Faulds G., Jeffery R. et al. 1998. The effect of novel polymorphisms in the interleukin-6 on IL-6 transcription and plasma levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369-1376.
10. Stuber F., Udalova I.A., Book M., Drutskaya L.N., Kuprash D.V. et al. 1995-96. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J. Inflamm. 46(1), 42-50.
11. Day C.P., Grove J., Daly A.K. et al. 1998. Tumor necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia. 41, 430-434.
12. 2 and problem of small samples. Mol. Biol. Evol. 6, 539-545.
13. Liu Y., Bernard H.U., Apt D. 1997. NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing. J. Biol. Chem. 272, 10739-10745.
14. Wilson A.G., Symons J.A., McDowell T.L. et al. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA. 94, 3195-3199.
15. Messer G., Spengler U., Jung M.C. et al. 1991. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J. Exp. Med. 173, 209-219.
16. Davies F.E., Rollinson S.J., Rawstron A.C. et al. 2000. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J. Clinic. Oncol. 18, 2843-2851.
17. Neben K., Mytilineos J., Moehler T.M., Preiss A. et. al. 2002. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 100, 2263-2265.
18. Zheng C., Huang D., Bergenbrant S., Sundblad A. et. Al. 2000. Interleukin 6, tumor necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br. J. Haematol. 109, 39-45.